GUT: Proton pump inhibitors may lead to the risk of colorectal cancer

Proton pump inhibitor (PPI) is a drug commonly prescribed for a variety of gastric diseases, including digestive ulcer disease, and gastro-oesophageal reflux (GORD) esophagitis and Barrett
.

Histamine receptor antagonists (H2RA) are another acid-suppressing drugs that are suitable for similar situations.

Proton pump inhibitor (PPI) is a drug commonly prescribed for a variety of gastric diseases, including digestive ulcer disease, and gastro-oesophageal reflux (GORD) esophagitis and Barrett

 

The researchers collected patients treated with PPI and H2RA from 1990 to 2018 in the UK, and all patients were followed up to 2019
.

The Cox proportional hazards model is suitable for estimating the marginal HR and 95% CI value of colorectal cancer, and finally the model is weighted and analyzed using standardized mortality weights

 

The cohort of this study included 1,293,749 PPI and 292387 H2RA subjects, and the median duration of follow-up was 4.
9 years
.

Although PPI use was not associated with an increase in the overall risk of colorectal cancer (HR: 1.

Colon cancer

 

This study confirmed that although the use of any PPI is not associated with an increased risk of colorectal cancer compared with H2RA, long-term use may be associated with a moderate increase in the risk of this malignant tumor
.

This study confirmed that although the use of any PPI is not associated with an increased risk of colorectal cancer compared with H2RA, long-term use may be associated with a moderate increase in the risk of this malignant tumor
.

 

 

Original source:

Devin Abrahami.

Proton pump inhibitors and risk of colorectal cancer.
Leave a message here